Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as a dry‑powder inhalation formulation for oral inhalation use. It provides bronchodilation for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD) in adults. GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow.

- Asthma: improves long‑term control and reduces symptoms in adults with persistent asthma. - Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation and reduces exacerbation risk in adults with COPD. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity in susceptible individuals.

Formoterol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Throat irritation: mild discomfort or dryness in the throat. - Cough: transient coughing after inhalation. - Headache: mild to moderate headache. - Tremor: fine muscle tremor, often of the hands. - Palpitations: sensation of rapid or irregular heartbeat. - Nasal congestion: mild blockage of the nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Hypokalemia: low blood potassium levels detectable on laboratory testing. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose, particularly in diabetic patients. - Pulmonary hypertension worsening: potential aggravation of existing pulmonary hypertension.

When using Oxis Turbohaler, consider the following safety measures:

- Assess patient suitability: confirm diagnosis of asthma or COPD before initiating therapy. - Review risk for cardiovascular events : evaluate patient’s cardiac history . - Monitor lung function : schedule regular spirometry assessments . - Avoid concomitant use of non‑ ­   - Avoid the   - Store at room temperature : keep the inhaler ​​   -   -  - 

The     

---      ",